According to a recent LinkedIn post from Segmed, the company is collaborating with iMerit Technology and Advocate Health on an open-source, annotated 3D mammogram dataset intended to support AI development for breast cancer detection. The dataset reportedly comprises biopsy-confirmed Digital Breast Tomosynthesis studies reviewed by U.S. board-certified radiologists and enhanced with expert lesion segmentation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests this initiative is aimed at making clinically validated imaging data more accessible to researchers, potentially lowering barriers for AI model development in medical imaging. For investors, broader adoption of such open datasets could strengthen Segmed’s role in the healthcare AI data ecosystem, enhancing its attractiveness as a partner for diagnostics firms while indirectly supporting long-term demand for its data infrastructure and curation services.